NasdaqGM:PTGXBiotechs
Why Protagonist Therapeutics (PTGX) Is Up 6.8% After Swinging to Q2 Profitability and Expanding ESOP
In August 2026, Protagonist Therapeutics reported second-quarter 2026 results showing net income of US$162.85 million, reversing a prior-year net loss and delivering basic earnings per share from continuing operations of US$2.47 versus a loss per share of US$0.55.
Alongside this earnings turnaround, the company closed multiple employee stock ownership plan-related shelf registrations over recent years and filed a new US$88.28 million common stock ESOP offering, underlining an ongoing...